Australia's most trusted
source of pharma news
Posted 4 June 2026 AM
Despite headwinds in the headlines, the first quarter of 2026 saw solid growth for the pharmaceutical industry overall, with eight of the top pharmas reporting double digit growth compared to the same period last year.
The list was bookended by obesity giants, with Eli Lilly dominating the market with a 56 per cent growth in revenues for the first quarter this year compared to Q1 in 2025. Fierce Pharma, which compiled the list, noted that this beat the already ambitious analyst consensus estimate by 13 per cent.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.